SEC Form 4 · accession 0001144204-15-066456
CorMedix Inc. · CRMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Duffy
Director
Period of report
Nov 13, 2015
Accepted (ET)
Nov 17, 2015 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001410098
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value per share | holding | — | — | — | 53,223 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Phantom StockF8,F7 | — | Nov 13, 2015 | A | 594 | A | — | — | Common Stock | 594 | 594 | D |
| Stock Option (right to buy)F1 | $2.02 | holding | — | — | — | — | Jan 9, 2024 | Common Stock, $0.001 par value per share | 150,000 | 150,000 | D |
| Stock Option (right to buy)F2 | $2.02 | holding | — | — | — | — | Jan 9, 2024 | Common Stock, $0.001 par value per share | 30,000 | 30,000 | D |
| Stock Option (right to buy)F3 | $0.90 | holding | — | — | — | — | Mar 20, 2023 | Common Stock, $0.001 par value per share | 100,000 | 100,000 | D |
| Stock Option (right to buy)F4 | $0.68 | holding | — | — | — | — | Dec 5, 2022 | Common Stock, $0.001 par value per share | 125,000 | 125,000 | D |
| Warrant (right to purchase Common Stock)F5 | $0.40 | holding | — | — | — | Nov 13, 2012 | Nov 13, 2017 | Common Stock, $0.001 par value per share | 25,000 | 25,000 | D |
| Stock Option (right to buy)F2 | $0.29 | holding | — | — | — | — | Jan 6, 2022 | Common Stock, $0.001 par value per share | 5,000 | 5,000 | D |
| Stock Option (right to buy)F6 | $0.28 | holding | — | — | — | — | Nov 21, 2021 | Common Stock, $0.001 par value per share | 15,000 | 15,000 | D |
| Stock Option (right to buy)F2 | $5.62 | holding | — | — | — | — | Mar 1, 2025 | Common Stock, $0.001 par value per share | 50,000 | 50,000 | D |
Explanation of responses
- F1These options vested 100% on January 10, 2014.
- F2These options vest in full on the first anniversary of the date of grant.
- F3These options vest quarterly over two years.
- F4These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- F5On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
- F6The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- F7Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo
- F8These shares were credited automatically to the reporting person's account pursuant to the reporting person's election to defer the receipt of cash compensation of directors fees.